These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 29761628)

  • 1. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
    Dhiman R; Singh R
    IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.
    Lin MY; Ottenhoff TH
    Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):15-29. PubMed ID: 18393920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Yang L; Hu X; Chai X; Ye Q; Pang J; Li D; Hou T
    Drug Discov Today; 2022 Jan; 27(1):326-336. PubMed ID: 34537334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
    Bhat ZS; Rather MA; Maqbool M; Ahmad Z
    Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents.
    Evans JC; Mizrahi V
    Curr Opin Microbiol; 2018 Oct; 45():39-46. PubMed ID: 29482115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.
    Mi J; Gong W; Wu X
    Biomed Res Int; 2022; 2022():5099312. PubMed ID: 35252448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remembering the Host in Tuberculosis Drug Development.
    Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
    J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection.
    Lin MY; Ottenhoff TH
    Biol Chem; 2008 May; 389(5):497-511. PubMed ID: 18953716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
    Hudson SA; McLean KJ; Munro AW; Abell C
    Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
    Kiran D; Podell BK; Chambers M; Basaraba RJ
    Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Sawicki R; Ginalska G
    Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
    Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
    J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the messengers: Serine/threonine protein kinases as potential targets for antimycobacterial drug development.
    Khan MZ; Kaur P; Nandicoori VK
    IUBMB Life; 2018 Sep; 70(9):889-904. PubMed ID: 29934969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development.
    Tanner L; Denti P; Wiesner L; Warner DF
    IUBMB Life; 2018 Sep; 70(9):926-937. PubMed ID: 29934964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
    Xu Z; Gao C; Ren QC; Song XF; Feng LS; Lv ZS
    Eur J Med Chem; 2017 Oct; 139():429-440. PubMed ID: 28818767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targets in M. tuberculosis: search for new drugs.
    Lamichhane G
    Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focusing on DNA Repair and Damage Tolerance Mechanisms in Mycobacterium tuberculosis: An Emerging Therapeutic Theme.
    Mittal P; Sinha R; Kumar A; Singh P; Ngasainao MR; Singh A; Singh IK
    Curr Top Med Chem; 2020; 20(5):390-408. PubMed ID: 31924156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.